{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:15:40Z","timestamp":1781892940700,"version":"3.54.5"},"reference-count":109,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Breast cancer is a significant global health concern, and the discovery of endocrine therapy has played a crucial role in the treatment of estrogen-positive breast cancer. However, these therapies are often associated with osteoporosis-related adverse events, which increase the risk of fractures in breast cancer patients and can result in limited mobility and reduced quality of life. Previous studies have shown that osteoporosis is essential side effects of the breast cancer therapy, although the exact mechanisms remain mostly unclear. Current clinical treatments, such as bisphosphonates, cause side effects and may impact the therapeutic response to endocrine drugs. In this review, we explore the likelihood of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy and discuss the involved mechanisms as well as the therapeutic potential of drugs and drug combination strategies.<\/jats:p>","DOI":"10.3389\/fonc.2023.1218206","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T15:25:56Z","timestamp":1688743556000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Jing","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21754","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA: A Cancer J Clin"},{"key":"B3","first-page":"1","article-title":"Guidelines for the diagnosis and treatment of breast cancer (2022 edition)","volume-title":"Chinese Journal of rational drug use","year":"2022"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds055","article-title":"Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM","volume":"23","author":"Hadji","year":"2012","journal-title":"Ann Oncol"},{"key":"B5","article-title":"Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen","author":"Lahti","year":"1993","journal-title":"Obstet Gynecol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4414-z","article-title":"Estrogen therapy for osteoporosis in the modern era","volume":"29","author":"Levin","year":"2018","journal-title":"Osteoporosis Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27987","article-title":"Estrogen receptors and human disease","volume":"116","author":"Deroo","year":"2006","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600596","article-title":"Alcohol, tobacco and breast cancer \u2013 collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease","volume":"87","year":"2002","journal-title":"Br J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv156","article-title":"Alcohol consumption and breast cancer risk by estrogen receptor status: in a pooled analysis of 20 studies","volume":"45","author":"Jung","year":"2015","journal-title":"Int J Epidemiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1186\/s13018-021-02821-8","article-title":"Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"J Orthopaedic Surg Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3757","article-title":"The prevalence of osteoporosis in China, a nationwide, multicenter DXA survey","volume":"34","author":"Zeng","year":"2019","journal-title":"J Bone Mineral Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03119","article-title":"Pharmacogenomics and endocrine therapy in breast cancer","volume":"38","author":"Hayes","year":"2020","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00366","article-title":"Effect of tamoxifen on the risk of osteoporosis and osteoporotic fracture in younger breast cancer survivors: a nationwide study","volume":"10","author":"Lee","year":"2020","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.breast.2021.09.010","article-title":"The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada","volume":"60","author":"Blanchette","year":"2021","journal-title":"Breast"},{"key":"B16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00198-018-4758-4","article-title":"Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations","volume":"30","author":"Hamood","year":"2019","journal-title":"Osteoporosis Int"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30116-5","article-title":"Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial","volume":"19","author":"De Placido","year":"2018","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32205","article-title":"Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study","volume":"145","author":"van Hellemond","year":"2019","journal-title":"Int J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.44.7805","article-title":"Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27\u2013a randomized controlled phase III trial","volume":"31","author":"Goss","year":"2013","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e403","article-title":"Osteoporotic fractures of the spine, hip, and other locations after adjuvant endocrine therapy with aromatase inhibitors in breast cancer patients: a meta-analysis","volume":"35","author":"Lee","year":"2020","journal-title":"J Korean Med Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.527","article-title":"Bone safety profile of steroidal aromatase inhibitor in comparison to non-steroidal aromatase inhibitors in postmenopausal women with breast cancer: a network meta-analysis","volume":"39","author":"Chen","year":"2021","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230)","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Mineral Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2007.06.004","article-title":"Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole","volume":"41","author":"Confavreux","year":"2007","journal-title":"Prev bisphosphonates Bone"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01228-2","article-title":"Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial","volume":"124","author":"Sestak","year":"2021","journal-title":"Br J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn762","article-title":"Effects of exemestane and tamoxifen on bone health within the tamoxifen exemestane adjuvant multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy","volume":"20","author":"Hadji","year":"2009","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0959-8049(02)00280-0","article-title":"Role of LHRH agonists in premenopausal women with oestrogen receptor-positive breast cancer: the ZEBRA experience","volume":"38","author":"Jonat","year":"2002","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.05.023","article-title":"Estrogen signaling: an emanating therapeutic target for breast cancer treatment","volume":"177","author":"Saha","year":"2019","journal-title":"Eur J Medicinal Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/bcr79","article-title":"Estrogen receptor transcription and transactivation estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action","volume":"2","author":"Hewitt","year":"2000","journal-title":"Breast Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.20751","article-title":"Breast cancer treatment","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3518","article-title":"Progesterone signalling in breast cancer: a neglected hormone coming into the limelight","volume":"13","author":"Brisken","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.3390\/cancers14071776","article-title":"Estrogens and progestins cooperatively shift breast cancer cell metabolism","volume":"14","author":"Ward","year":"2022","journal-title":"Cancers"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal WomenPrincipal results from the women's health initiative randomized controlled trial","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1500","article-title":"Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women","volume":"304","author":"Chlebowski","year":"2010","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3645","article-title":"Association of circulating progesterone with breast cancer risk among postmenopausal women","volume":"3","author":"Trabert","year":"2020","journal-title":"JAMA Network Open"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nature14583","article-title":"Progesterone receptor modulates ER\u03b1 action in breast cancer","volume":"523","author":"Mohammed","year":"2015","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3541","article-title":"Breast cancer suppression by progesterone receptors is mediated by their modulation of estrogen receptors and RNA polymerase III","volume":"77","author":"Finlay-Schultz","year":"2017","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"111433","DOI":"10.1016\/j.yexcr.2019.05.014","article-title":"Ligand-activated progesterone receptor b activates transcription factor EB to promote autophagy in human breast cancer cells","volume":"382","author":"Tan","year":"2019","journal-title":"Exp Cell Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801152","article-title":"Progesterone receptor attenuates STAT1-mediated IFN signaling in breast cancer","volume":"202","author":"Goodman","year":"2019","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nature09495","article-title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis","volume":"468","author":"Gonzalez-Suarez","year":"2010","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-02872-1","article-title":"Bone loss induced by cancer treatments in breast and prostate cancer patients","volume":"24","author":"Casta\u00f1eda","year":"2022","journal-title":"Clin Trans Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI4682","article-title":"Estrogen\u2019s bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells","volume":"103","author":"Sunyer","year":"1999","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.46.28890","article-title":"Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production*","volume":"271","author":"Kimble","year":"1996","journal-title":"J Biol Chem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06368.x","article-title":"Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion","volume":"13","author":"Poli","year":"1994","journal-title":"EMBO J"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2023.01.003","article-title":"Obacunone targets macrophage migration inhibitory factor (MIF) to impede osteoclastogenesis and alleviate ovariectomy-induced bone loss","author":"He","year":"2023","journal-title":"J Advanced Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2016.02.001","article-title":"p38\u03b1 MAPK regulates lineage commitment and OPG synthesis of bone marrow stromal cells to prevent bone loss under physiological and pathological conditions","volume":"6","author":"Cong","year":"2016","journal-title":"Stem Cell Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1210\/endo.140.9.7131","article-title":"Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells*","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e392","DOI":"10.1002\/ctm2.392","article-title":"A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species","volume":"11","author":"Hong","year":"2021","journal-title":"Clin Trans Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.3390\/ijms20143576","article-title":"Reactive oxygen species in osteoclast differentiation and possible pharmaceutical targets of ROS-mediated osteoclast diseases","volume":"20","author":"Agidigbi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1103611","article-title":"ROS-scavenging hydrogel as protective carrier to regulate stem cells activity and promote osteointegration of 3D printed porous titanium prosthesis in osteoporosis","volume":"11","author":"Ding","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"6460","DOI":"10.1038\/s41598-017-06614-0","article-title":"Estrogen regulates bone turnover by targeting RANKL expression in bone lining cells","volume":"7","author":"Streicher","year":"2017","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010764200","article-title":"Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-\u03baB ligand (RANKL)-induced JNK activation*","volume":"276","author":"Srivastava","year":"2001","journal-title":"J Biol Chem"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13718","article-title":"Regulation of TRPV5 transcription and expression by E2\/ER\u03b1 signalling contributes to inhibition of osteoclastogenesis","volume":"22","author":"Song","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.24700","article-title":"Estrogen inhibits RANKL-induced osteoclastic differentiation by increasing the expression of TRPV5 channel","volume":"115","author":"Chen","year":"2014","journal-title":"J Cell Biochem"},{"key":"B54","doi-asserted-by":"publisher","first-page":"108168","DOI":"10.1016\/j.pharmthera.2022.108168","article-title":"Advances in pathogenesis and therapeutic strategies for osteoporosis","volume":"237","author":"Song","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.25102","article-title":"Estrogen enhances activity of wnt signaling during osteogenesis by inducing Fhl1 expression","volume":"116","author":"Wu","year":"2015","journal-title":"J Cell Biochem"},{"key":"B56","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/ijms17030349","article-title":"MicroRNAs in osteoclastogenesis and function: potential therapeutic targets for osteoporosis","volume":"17","author":"Ji","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201909_18827","article-title":"MiR-373 promotes the osteogenic differentiation of BMSCs from the estrogen deficiency induced osteoporosis","author":"Li X-LW","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.7150\/thno.34493","article-title":"Circulating miR-338 cluster activities on osteoblast differentiation: potential diagnostic and therapeutic targets for postmenopausal osteoporosis","volume":"9","author":"Lin","year":"2019","journal-title":"Theranostics"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.7150\/thno.55041","article-title":"Identification of the canonical and noncanonical role of miR-143\/145 in estrogen-deficient bone loss","volume":"11","author":"Xu","year":"2021","journal-title":"Theranostics"},{"key":"B60","doi-asserted-by":"publisher","first-page":"111171","DOI":"10.1016\/j.mce.2021.111171","article-title":"Estrogen promotes lncRNA H19 expression to regulate osteogenic differentiation of BMSCs and reduce osteoporosis via miR-532-3p\/SIRT1 axis","volume":"527","author":"Li","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26788","article-title":"Estrogen inhibits osteoclasts formation and bone resorption via microRNA-27a targeting PPAR\u03b3 and APC","volume":"234","author":"Guo","year":"2019","journal-title":"J Cell Physiol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.24471","article-title":"Down-regulation of miR-21 biogenesis by estrogen action contributes to osteoclastic apoptosis","volume":"114","author":"Sugatani","year":"2013","journal-title":"J Cell Biochem"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.07.025","article-title":"Estrogen prevents bone loss via estrogen receptor \u03b1 and induction of fas ligand in osteoclasts","volume":"130","author":"Nakamura","year":"2007","journal-title":"Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.7150\/thno.42982","article-title":"miR-128 plays a critical role in murine osteoclastogenesis and estrogen deficiency-induced bone loss","volume":"10","author":"Shen","year":"2020","journal-title":"Theranostics"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06076-x","article-title":"Estrogen regulates duodenal calcium absorption through differential role of estrogen receptor on calcium transport proteins","volume":"65","author":"Nie","year":"2020","journal-title":"Digestive Dis Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1097\/00041552-199907000-00005","article-title":"Biochemical markers of bone turnover","volume":"8","author":"Hart","year":"1999","journal-title":"Curr Opin Nephrol Hypertension"},{"key":"B67","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","article-title":"UK Clinical guideline for the prevention and treatment of osteoporosis","volume":"17","author":"Gregson","year":"2022","journal-title":"Arch Osteoporosis"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporosis Int"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06667-6","article-title":"A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis","volume":"34","author":"Belaya","year":"2023","journal-title":"Osteoporosis Int"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.146728","article-title":"Mitochondrial Sirt3 contributes to the bone loss caused by aging or estrogen deficiency","volume":"6","author":"Ling","year":"2021","journal-title":"JCI Insight"},{"key":"B71","doi-asserted-by":"publisher","first-page":"114347","DOI":"10.1016\/j.biopha.2023.114347","article-title":"Isosinensetin alleviates estrogen deficiency-induced osteoporosis via suppressing ROS-mediated NF-\u03baB\/MAPK signaling pathways","volume":"160","author":"Qin","year":"2023","journal-title":"Biomedicine Pharmacother"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01046","article-title":"Boldine ameliorates estrogen deficiency-induced bone loss via inhibiting bone resorption","volume":"9","author":"Chen","year":"2018","journal-title":"Front Pharmacol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.2c00192","article-title":"A novel prenylflavonoid icariside I ameliorates estrogen deficiency-induced osteoporosis via simultaneous regulation of osteoblast and osteoclast differentiation","volume":"6","author":"Chen","year":"2023","journal-title":"ACS Pharmacol Trans Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2023.01.017","article-title":"Corylifol a protects against ovariectomized-induced bone loss and attenuates RANKL-induced osteoclastogenesis via ROS reduction, ERK inhibition, and NFATc1 activation","volume":"196","author":"Xu","year":"2023","journal-title":"Free Radical Biol Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06672-3","article-title":"Management of bone loss due to endocrine therapy during cancer treatment","volume":"34","author":"Khan","year":"2023","journal-title":"Osteoporosis Int"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01696","article-title":"Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline","volume":"37","author":"Shapiro","year":"2019","journal-title":"J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1158\/1538-7445.SABCS21-P1-13-04","article-title":"Abstract P1-13-04: evaluation of the impact vitamin d and calcium supplementation on bone mineral density in breast cancer patients using or not taking aromatase inhibitors: 5-year follow-up","volume":"82","author":"Antonini","year":"2022","journal-title":"Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.914182","article-title":"Associated factors for osteoporosis and fracture in Chinese elderly","volume":"25","author":"Wang","year":"2019","journal-title":"Med Sci Monit"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009034","article-title":"Association between tea consumption and osteoporosis: a meta-analysis","volume":"96","author":"Sun","year":"2017","journal-title":"Medicine"},{"key":"B80","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00198-019-04908-9","article-title":"Effects of a 3-month weight-bearing and resistance exercise training on circulating osteogenic cells and bone formation markers in postmenopausal women with low bone mass","volume":"30","author":"Pasqualini","year":"2019","journal-title":"Osteoporosis Int"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.3390\/ijms20092213","article-title":"Medical treatment for osteoporosis: from molecular to clinical opinions","volume":"20","author":"Chen","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.12.005","article-title":"Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial","volume":"108","author":"Livi","year":"2019","journal-title":"Eur J Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00632","article-title":"Improvement of bone physiology and life quality due to association of risedronate and anastrozole","volume":"8","author":"Monda","year":"2017","journal-title":"Front Pharmacol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3100-7","article-title":"Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial","volume":"26","author":"Greenspan","year":"2015","journal-title":"Osteoporosis Int"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06683-0","article-title":"Prevention of aromatase inhibitor\u2013induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer","volume":"34","author":"Mugnier","year":"2023","journal-title":"Osteoporosis Int"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtumed.2020.10.017","article-title":"Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells","volume":"16","author":"Sheweita","year":"2021","journal-title":"J Taibah Univ Med Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-1083-y","article-title":"The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial","volume":"21","author":"Waltman","year":"2010","journal-title":"Osteoporosis Int"},{"key":"B88","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/joim.12339","article-title":"Efficacy, effectiveness and side effects of medications used to prevent fractures","volume":"277","author":"Reid","year":"2015","journal-title":"J Internal Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijsu.2019.03.004","article-title":"Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: a meta-analysis","volume":"66","author":"Yuan","year":"2019","journal-title":"Int J Surg"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2012.02.002","article-title":"Antiresorptive therapies in oncology and their effects on cancer progression","volume":"38","author":"Bundred","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1814731","article-title":"Denosumab for cancer-related bone loss","volume":"20","author":"Dell\u2019Aquila","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B94","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European Guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporosis Int"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with RaloxifeneResults from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"B96","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13058-021-01431-w","article-title":"Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer","volume":"23","author":"Lain\u00e9","year":"2021","journal-title":"Breast Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.108","article-title":"Parathyroid hormone analogues in the treatment of osteoporosis","volume":"7","author":"Kraenzlin","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(18)30754-2","article-title":"Teriparatide vs risedronate for osteoporosis","volume":"391","author":"Liel","year":"2018","journal-title":"Lancet"},{"key":"B100","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41413-019-0050-2","article-title":"Connexin 43 hemichannels protect bone loss during estrogen deficiency","volume":"7","author":"Ma","year":"2019","journal-title":"Bone Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-160281","article-title":"Mechanism of bushen jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment","volume":"18","author":"Huang","year":"2017","journal-title":"Cancer Biomarkers"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.16448\/j.cjtcm.2022.0720","article-title":"Based on association rules and factor analysis to explore the rule of traditional Chinese medicine prescription for bone loss after endocrine therapy for breast cancer","volume":"34","author":"Jiayi","year":"2022","journal-title":"Clin J Traditional Chin Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"104334","DOI":"10.1016\/j.phrs.2019.104334","article-title":"Mechanisms explaining the efficacy of psoralidin in cancer and osteoporosis, a review","volume":"147","author":"Xin","year":"2019","journal-title":"Pharmacol Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"120601","DOI":"10.1016\/j.carbpol.2023.120601","article-title":"Structural characterization and anti-osteoporosis effects of polysaccharide purified from eucommia ulmoides Oliver cortex based on its modulation on bone metabolism","volume":"306","author":"Song","year":"2023","journal-title":"Carbohydr Polymers"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.920931","article-title":"Total flavonoids of drynariae rhizoma improve glucocorticoid-induced osteoporosis of rats: UHPLC-MS-Based qualitative analysis, network pharmacology strategy and pharmacodynamic validation","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Endocrinol"},{"key":"B106","first-page":"6084","article-title":"progress on mechanism of active components of Chinese materiamedica in treatment of osteoporosis based on signaling pathway","volume":"51","author":"Jin-long","year":"2020","journal-title":"Chinese Traditional and Herbal Drugs"},{"key":"B107","doi-asserted-by":"publisher","first-page":"12292","DOI":"10.3390\/ijms222212292","article-title":"Resistance to CDK4\/6 inhibitors in estrogen receptor-positive breast cancer","volume":"22","author":"Scheidemann","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125679","article-title":"Angiocrine signals regulate quiescence and therapy resistance in bone metastasis","volume":"4","author":"Singh","year":"2019","journal-title":"JCI Insight"},{"key":"B109","doi-asserted-by":"publisher","first-page":"9903336","DOI":"10.1155\/2023\/9903336","article-title":"Substance p-mediated vascular protection ameliorates bone loss","volume":"2023","author":"Kim","year":"2023","journal-title":"Oxid Med Cell Longev"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1218206\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T15:26:04Z","timestamp":1688743564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1218206\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":109,"alternative-id":["10.3389\/fonc.2023.1218206"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1218206","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"article-number":"1218206"}}